Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.28 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 701 | 0.85 |
| pathways Reactome | 5 pathways; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 1399
Sealed predictions
- ACSL1 in dopamine neurons, braak-0.29 (p 0.457) → +0.45 (p 0.224)receipt 1406
Swarm cases
receipt 1406: ACSL1 in dopamine neurons, braak
- power
- full sample +0.01 (p 0.969, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.01 (p 0.983, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.04 (p 0.881, n 18). could be the mix.
- skeptic
- leave-one-out range -0.13 to +0.12, sign flips 6; without severely affected donors +0.01 (p 0.969, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ACSL1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts